FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947110460> ?p ?o ?g. }

• W2947110460 abstract "6627 Background: The rising cost of anti-cancer therapy has motivated recent efforts to quantify the overall value of new cancer treatments. Multi-criteria decision analysis offers a novel approach to establish an explicit framework to evaluate new cancer treatments. Methods: We recruited a diverse multi-stakeholder group who identified and weighted key criteria to establish the Drug Assessment Framework (DAF). Strength of evidence (SOE) modifiers deducted points for lower quality evidence. Through one-on-one meetings with stakeholders, face and content validity of the DAF were established in an iterative process. Construct validity assessed the degree to which DAF scores were associated with the pan-Canadian oncology drug review (pCODR) funding decisions and European Society for Medical Oncology Magnitude of Clinical Benefit score (ESMO-MCBS, version 1.1). Sensitivity analyses were performed on the final results. Results: The final validated DAF includes ten criteria: overall survival, progression-free survival, response rate, quality-of-life, toxicity, unmet need, equity, feasibility, disease severity and caregiver well-being. The first five clinical benefit criteria represent 64% of the total weight. DAF scores range from 0 to 300, reflecting both the expected impact of the drug and the quality of the supporting evidence. When the DAF was retrospectively applied to the last 60 drugs (in blinded fashion) reviewed by pCODR (2015-2018), the mean total DAF score was 94 (range, 18-179). Drugs with positive pCODR funding recommendation had higher DAF scores than drugs not recommended for reimbursement (103 vs. 63, t-test p = 0.0007). Funded drugs had fewer SOE points deducted than those that were not funded (median 0 vs. 24 points deducted, Wilcoxon p = 0.03). The correlation coefficient for DAF and ESMO-MCBS was 0.37 (95% CI, 0.10 to 0.59). Sensitivity analyses that varied the subjective criteria either positively or negatively did not change the results. Conclusions: Using a structured and explicit approach, a criterion-based valuation framework was designed and validated. The DAF can provide a transparent and consistent method to value and prioritize cancer drugs, in order to facilitate the delivery of affordable cancer care." @default.
• W2947110460 created "2019-06-07" @default.
• W2947110460 creator A5002447665 @default.
• W2947110460 creator A5008282524 @default.
• W2947110460 creator A5012748795 @default.
• W2947110460 creator A5013495579 @default.
• W2947110460 creator A5031861481 @default.
• W2947110460 creator A5064185000 @default.
• W2947110460 creator A5073462876 @default.
• W2947110460 creator A5080580460 @default.
• W2947110460 creator A5089779419 @default.
• W2947110460 date "2019-05-20" @default.
• W2947110460 modified "2023-09-26" @default.
• W2947110460 title "A weighted criterion-based approach to value assessment of oncology drugs." @default.
• W2947110460 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.6627" @default.
• W2947110460 hasPublicationYear "2019" @default.
• W2947110460 type Work @default.
• W2947110460 sameAs 2947110460 @default.
• W2947110460 citedByCount "0" @default.
• W2947110460 crossrefType "journal-article" @default.
• W2947110460 hasAuthorship W2947110460A5002447665 @default.
• W2947110460 hasAuthorship W2947110460A5008282524 @default.
• W2947110460 hasAuthorship W2947110460A5012748795 @default.
• W2947110460 hasAuthorship W2947110460A5013495579 @default.
• W2947110460 hasAuthorship W2947110460A5031861481 @default.
• W2947110460 hasAuthorship W2947110460A5064185000 @default.
• W2947110460 hasAuthorship W2947110460A5073462876 @default.
• W2947110460 hasAuthorship W2947110460A5080580460 @default.
• W2947110460 hasAuthorship W2947110460A5089779419 @default.
• W2947110460 hasConcept C105795698 @default.
• W2947110460 hasConcept C126322002 @default.
• W2947110460 hasConcept C143998085 @default.
• W2947110460 hasConcept C2776291640 @default.
• W2947110460 hasConcept C33923547 @default.
• W2947110460 hasConcept C71924100 @default.
• W2947110460 hasConceptScore W2947110460C105795698 @default.
• W2947110460 hasConceptScore W2947110460C126322002 @default.
• W2947110460 hasConceptScore W2947110460C143998085 @default.
• W2947110460 hasConceptScore W2947110460C2776291640 @default.
• W2947110460 hasConceptScore W2947110460C33923547 @default.
• W2947110460 hasConceptScore W2947110460C71924100 @default.
• W2947110460 hasLocation W29471104601 @default.
• W2947110460 hasOpenAccess W2947110460 @default.
• W2947110460 hasPrimaryLocation W29471104601 @default.
• W2947110460 hasRelatedWork W2022460880 @default.
• W2947110460 hasRelatedWork W2031806788 @default.
• W2947110460 hasRelatedWork W2034125309 @default.
• W2947110460 hasRelatedWork W2050652676 @default.
• W2947110460 hasRelatedWork W2110712321 @default.
• W2947110460 hasRelatedWork W2119493390 @default.
• W2947110460 hasRelatedWork W2293326301 @default.
• W2947110460 hasRelatedWork W2505201528 @default.
• W2947110460 hasRelatedWork W2773034404 @default.
• W2947110460 hasRelatedWork W2790084679 @default.
• W2947110460 hasRelatedWork W2801353374 @default.
• W2947110460 hasRelatedWork W2954378228 @default.
• W2947110460 hasRelatedWork W2964244141 @default.
• W2947110460 hasRelatedWork W2971383372 @default.
• W2947110460 hasRelatedWork W2980345806 @default.
• W2947110460 hasRelatedWork W2988891807 @default.
• W2947110460 hasRelatedWork W2996114543 @default.
• W2947110460 hasRelatedWork W3082618359 @default.
• W2947110460 hasRelatedWork W3103116113 @default.
• W2947110460 hasRelatedWork W3195315042 @default.
• W2947110460 isParatext "false" @default.
• W2947110460 isRetracted "false" @default.
• W2947110460 magId "2947110460" @default.
• W2947110460 workType "article" @default.